Donald  Abbey net worth and biography

Donald Abbey Biography and Net Worth

EVP of DexCom

Donald (“Don”) Abbey is Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs

Don assumed the role of Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs in January 2017, and previously served as Executive Vice President, Quality from May 2016 to January 2017.

Don has 30+ years of medical device and pharmaceutical industry experience. Prior to Dexcom, Don served in executive roles for Becton Dickinson (the acquirer of CareFusion which itself was spun off from Cardinal Health), including as Senior Vice President, Quality and Regulatory for Becton Dickinson, as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion, as Senior Vice President, Quality and Regulatory for CareFusion, and as Senior Vice President, Quality and Regulatory for Cardinal Health. Prior to 2007, Don held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare.

Don received a Bachelor of Science degree in Electrical Engineering from Washington State University and a Master of Business Administration from the University of Washington.

What is Donald Abbey's net worth?

The estimated net worth of Donald Abbey is at least $2.10 million as of April 4th, 2014. Mr. Abbey owns 28,143 shares of DexCom stock worth more than $2,095,528 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Abbey may own. Learn More about Donald Abbey's net worth.

How do I contact Donald Abbey?

The corporate mailing address for Mr. Abbey and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Donald Abbey's contact information.

Has Donald Abbey been buying or selling shares of DexCom?

Donald Abbey has not been actively trading shares of DexCom within the last three months. Most recently, Donald Abbey sold 8,050 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $264.68, for a transaction totalling $2,130,674.00. Learn More on Donald Abbey's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 9/9/2024.

Donald Abbey Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2020Sell8,050$264.68$2,130,674.00View SEC Filing Icon  
9/9/2019Sell5,843$149.85$875,573.55View SEC Filing Icon  
6/3/2019Sell9,030$121.08$1,093,352.40View SEC Filing Icon  
3/12/2019Sell7,653$142.79$1,092,771.87View SEC Filing Icon  
11/9/2018Sell10,550$149.30$1,575,115.00View SEC Filing Icon  
9/10/2018Sell2,303$143.76$331,079.28View SEC Filing Icon  
See Full Table

Donald Abbey Buying and Selling Activity at DexCom

This chart shows Donald Abbey's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $74.46
Low: $74.14
High: $75.76

50 Day Range

MA: $70.43
Low: $65.68
High: $76.27

2 Week Range

Now: $74.46
Low: $62.34
High: $142.00

Volume

3,230,709 shs

Average Volume

3,924,849 shs

Market Capitalization

$29.08 billion

P/E Ratio

44.59

Dividend Yield

N/A

Beta

1.17